AUTHORS
Jordan Lundberg, PharmD, Adithya Ghantae, PharmD2, Faythlynn Vanek3, Matthew Arango, PharmD4, Junan Li, PhD5, Stacy Artrip, MS, APRN-CNS, OCN6, Yazeed Sawalha, MD7, Timothy J Voorhees, MD,MSc8
AFFILIATIONS
1 The Ohio State University, Columbus, Ohio, United States
2 Novant Health Cancer Institiute, Charlotte, North Carolina, United States
3 The Ohio State University, Columbus, Ohio, United States
4 The Ohio State University, Columbus, Ohio, United States
5 The Ohio State University College of Pharmacy, Columbus, Ohio, United States
6 The Ohio State University, Columbus, Ohio, United States
7 The Ohio State University, Columbus, Ohio, United States
8 The Ohio State University, Columbus, Ohio, United States
ABSTRACT
Introduction: Patients with hematologic malignancies often require implanted ports for IV access and cancer treatment. A common complication of implanted ports is catheter occlusion with reported rates of 1-4%. To prevent occlusion, flushing protocols are implemented using a heparin or saline lock between accesses of the port. Available data supports saline as a non-inferior option with less overall complications compared to heparin. Given this, two practice changes were implemented at our institution, changing flushing frequency from monthly to every 1-3 months, and switching the primary agent to saline. We sought to determine if there was an increase in catheter occlusions and use of alteplase after the changes in our institutional flushing protocols.
Methods: We retrospectively collected data on patients with hematologic malignancies and implanted ports accessed in our outpatient clinics in 2 time periods: January 1, 2023, to June 30, 2023 (pre-cohort) and January 1, 2024, to June 30, 2025 (post-cohort). Our primary endpoint was incidence of port occlusions and was quantified using alteplase doses then normalized per 1000 ports accessed. We collected additional data on patients that received alteplase including age, gender, concurrent anticoagulation, number of alteplase doses and time between port accesses.
Results: We included 543 patients in the pre-cohort with a total of 1645 port accesses and 1,307 patients in the post-cohort with 5,373 port accesses. Patients that received alteplase in the pre-cohort (n=61) had a median age of 66 years old (range 23-87), 30 (49%) were male gender and 13 (21%) were on concurrent anticoagulation. Patients that received alteplase in the post-cohort (n=202) had a median age of 67 years old (range 22-86), 92 (46%) were male gender and 22 (11%) were on concurrent anticoagulation. We found no difference in the incidence of port occlusions between the two groups (69 vs 80 doses of alteplase per 1000 ports accessed in the pre- and post-change cohorts, respectively; p=0.1528). We did, however, find differences when examining subgroups stratified by time between port accesses, ≤30 days or >30 days, and type of implanted port, single vs double lumen. Patients in the post-cohort accessed on average ≤30 days apart had a significantly higher incidence of port occlusions (64 vs 127 doses of alteplase per 1000 ports accessed in pre- vs post-cohort, respectively; P<0.0001). Patients in the post-cohort accessed on average >30 days apart had a significantly higher incidence of port occlusions (64 vs 217 doses of alteplase per 1000 ports accessed in pre- vs post-cohort, respectively; P<0.0001). There was a statistically higher incidence of port occlusions in the post-cohort compared to pre-cohort in all subgroups (single lumen ≤ 30 days: 41 vs 14 doses of alteplase per 1000 ports accessed respectively, p=0.00038; single lumen >30 days: 77 vs 21 respectively, p<0.001; double lumen ≤ 30 days: 158 vs 94 respectively, p<0.0001; and double lumen >30 days: 286 vs 97 respectively, p<0.0001).
Conclusions: This is the largest study to date reviewing flushing interval in relation to port occlusions and showed that flushing using saline at a ≤ 30 days or >30-day interval leads to a higher rate of port occlusions than when using heparin, regardless of the type of implanted port.
DISCLOSURES
Faythlynn Vanek: No relevant conflicts of interest to declare.